Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Eikelboom, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Eikelboom, J.
Haematologica, Vol 89, Issue 5, 586-593
Copyright © 2004 by Ferrata Storti Foundation


Journal Article

Thromboprophylaxis practice patterns in two Western Australian teaching hospitals

JW Eikelboom, A Mazzarol, DJ Quinlan, R Beaver, J Williamson, Q Yi, GJ Hankey, and

Department of Hematology, Royal Perth Hospital, Wellington Street, Perth, WA, 6001. Australia. john.eikelboom@health.wa.gov.au

BACKGROUND AND OBJECTIVES: Evidence-based international guidelines recommend that all patients undergoing elective hip or knee arthroplasty receive thromboprophylaxis with low-molecular-weight heparin or adjusted-dose warfarin. Our objective was to determine what proportion of patients undergoing elective hip or knee arthroplasty actually receive recommended thromboprophylaxis according to international guidelines. DESIGN AND METHODS: We performed a prospective cohort study of 396 consecutive patients undergoing elective hip or knee arthroplasty between 1 May and 30 October, 2002. We collected baseline data, surgical and anesthetic details and recorded use of thromboprophylaxis and episodes of venous thromboembolism that occurred within 3 months of surgery. RESULTS: The mean age of the patients was 69.4 years (SD 11.5 years), and 62.2% (95% CI: 57.3 to 66.9%) were female. Hip arthroplasty was performed in 39.4% (34.6 to 44.2%) and knee arthroplasty in 57.1% (52.2 to 61.9%). Recommended thromboprophylaxis with low-molecular-weight heparin or warfarin was administered to 51.5% (46.6 to 56.4%). Objectively diagnosed venous thromboembolism occurred in 5.3% (3.3 to 8.0%) of patients; 3.5% (1.9 to 5.9%) of events occurred during hospitalization and 1.8% (0.7 to 3.6%) occurred following discharge from hospital. There was no significant reduction in the incidence of venous thromboembolism among patients treated with recommended thromboprophylaxis compared with those who did not but this is not a randomized comparison and is potentially confounded by the indication for treatment. INTERPRETATION AND CONCLUSIONS: Current thromboprophylaxis practice at our institutions falls substantially short of national and international guidelines. The reasons for low thromboprophylaxis use should be further explored and strategies for change implemented in order to optimize clinical practice.


This article has been cited by other articles:


Home page
J Bone Joint Surg BrHome page
B. T. Bjornara, T. E. Gudmundsen, and O. E. Dahl
Frequency and timing of clinical venous thromboembolism after major joint surgery
J Bone Joint Surg Br, March 1, 2006; 88-B(3): 386 - 391.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. Leizorovicz and P. Mismetti
Preventing Venous Thromboembolism in Medical Patients
Circulation, December 14, 2004; 110(24_suppl_1): IV-13 - IV-19.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.